Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOptiBiotix Health Regulatory News (OPTI)

Share Price Information for OptiBiotix Health (OPTI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 18.00
Bid: 17.00
Ask: 19.00
Change: 0.00 (0.00%)
Spread: 2.00 (11.765%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 17.25
OPTI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Commercial Appointments

1 Mar 2022 07:00

RNS Number : 0988D
OptiBiotix Health PLC
01 March 2022
 

OptiBiotix Health plc

("OptiBiotix" or the "Company")

 

Commercial Appointments

 

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, blood pressure, diabetes, announces the following appointments1: Zac Sniderman as Business Development & Sales Director North America, Shiraz Butt as E-Commerce Director and Karl Burkitt as Marketing Director.

 

Zac brings a broad experience developing a food and supplement ingredient businesses in North America working for Galenicum Speciality Ingredients, Jarrow Formulas and Best Ground International. He has an entrepreneurial mindset and an extensive network. He will focus on the development of ingredient sales to brand owners and contract manufacturers for both pro- and prebiotics in close cooperation with our established partners.

 

Shiraz has successfully developed the e-commerce businesses for a range of companies, such as PhD (now part of Science In Sports) and Iovate Health Sciences. He has built digital sales from the ground up into significant contributors to the success of the companies he has worked for. Shiraz will focus on developing the untapped e-commerce potential of our pro- and prebiotic brands such as SlimBiome Medical, Go-Figure and CholBiome.

 

Karl Burkitt has a rich career in which he developed and led the marketing and business development function in various branded and ingredient businesses, such as Novartis Consumer Health, Kerry Ingredients & Flavours and AB Mauri. Karl will lead our marketing function, on a part time basis, and work closely with the pro- and prebiotic commercial divisions on developing ingredient and consumer sales.

 

The above appointments expand the capabilities of our management team in line with our commercial strategy, which is to further expand ingredient sales, particularly in the large North American market, whilst developing our final product sales containing our unique ingredients.

 

René Kamminga, CEO of OptiBiotix Ltd, commented: "In the past 12 months we have established the credibility and brand awareness of our science-based ingredients SlimBiome®, OptiBiome, LeanBiome and LPLDL® ingredients, significantly growing sales to a wider number of reputable global brands in multiple markets. These appointments are a further investment to accelerate the growth of the Company and to broaden and deepen our income streams with a particular focus on North America and E-Commerce."

 

1These appointments are non-statutory director appointments in the Company or its subsidiaries.

 

For further information, please contact:

 

OptiBiotix Health plc

www.optibiotix.com

Stephen O'Hara, Chief Executive

Contact via Walbrook below

 

 

 

 

Cenkos Securities plc (Broker)

Tel: 020 7397 8900

Callum Davidson / Neil McDonald

 

Michael Johnson / Russell Kerr (Sales)

 

 

 

Walbrook PR Ltd

Mob: 07407 804 654

Alice Woodings

 

 

This communication is a "Reach" announcement. Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained in this announcement is of a non-regulatory nature. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRATPMRTMTJTBAT
Date   Source Headline
3rd Feb 20144:31 pmRNSFurther re Open Offer
30th Jan 20144:37 pmRNSOffer Document Posted
30th Jan 20144:36 pmRNSAnnual Financial Report
28th Nov 20137:00 amRNSChange of Name
26th Nov 20137:00 amRNSChange of Rule 26 Website Address
25th Nov 201311:57 amRNSHolding(s) in Company
20th Nov 20131:21 pmRNSHolding(s) in Company
18th Nov 201312:53 pmPRNNotice of GM and Directorate Change
1st Nov 20134:05 pmPRNPosting of Circular
8th Aug 20137:00 amPRNUpdate
2nd Aug 20137:00 amPRNIssue of Equity - Conversion of Debt, Directors Dealing
25th Apr 20137:00 amPRNHalf-yearly Report
14th Mar 201311:19 amPRNResult of AGM, General Meeting and Issue of Equity
19th Feb 20137:00 amPRNNotice of General Meeting, AGM and Placing
31st Jan 20133:09 pmPRNFinal Results
6th Dec 201212:38 pmRNSNew Contract Win
15th Oct 20128:21 amRNSNew Product Approvals
12th Oct 20127:00 amPRNUpdate and Directorate Changeange
14th Sep 201211:30 amRNSProduct Approval
6th Sep 20127:00 amPRNNew Product Sales
3rd Sep 201210:54 amPRNChange of Adviser
3rd Sep 20128:55 amRNSNew Product Announcement
2nd Jul 20123:56 pmPRNTotal Voting Rights
18th Jun 201211:49 amPRNResult of General Meeting
14th Jun 201210:32 amPRNFurther re placing, update and grant of options
1st Jun 20123:22 pmPRNTotal Voting Rights
24th May 20127:00 amPRNPosting of Circular and change of registered office
22nd May 201211:30 amPRNPlacing and update
30th Apr 201212:00 pmPRNHalf-yearly Report
29th Feb 20121:20 pmPRNTotal Voting Rights
8th Feb 20127:01 amPRNIssue of Equity
8th Feb 20127:00 amPRNTrading Update
24th Jan 20127:00 amPRNHolding(s) in Company
19th Dec 201112:10 pmPRNResult of Annual General Meeting and Statement
2nd Dec 20117:00 amPRNDirectorate change and update
31st Oct 20112:16 pmPRNPosting of report and accounts
28th Oct 20117:00 amPRNFinal Results
23rd Sep 201110:38 amPRNShare Price Movement and Update
9th Sep 20117:00 amPRNFirst Day of Dealings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.